COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
27/03/2019
Designation offers potential for expedited development and review NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel [...]
CFN Media Interviews High Hampton’s CEO to Discuss 2019 Catalysts
27/03/2019
SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an [...]
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
27/03/2019
NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print [...]
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
27/03/2019
OTTAWA, March 27, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF) , today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal [...]
Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
27/03/2019
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa., March 27 [...]
Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG
27/03/2019
Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination More Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go Forward Every Vote is [...]
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
27/03/2019
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who [...]
Genfit: GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS
27/03/2019
FOR IMMEDIATE RELEASE GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS Lille (France), Cambridge (Massachusetts, United States), March 27, 2019 - 9.00 am CET – GENFIT [...]
Genfit: GENFIT ANNONCE LA SUSPENSION DU COURS DE SES ACTIONS ET DE SES OCEANES SUR EURONEXT PARIS ET EURONEXT ACCESS
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Aino Health AB (publ): Aino Health and Veritas Pension Insurance will launch Work Ability Support Service Center
27/03/2019
27 th of March, 2019 Aino Health together with Veritas Pension Insurance co-created and will launch a unique work ability support service for Veritas' customers. The service will be operational in Q2 2019. In the first [...]
Genfit: GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
27/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market Lille (France), Cambridge (Massachusetts, United States), March 27, 2019 – GENFIT SA (Euronext: GNFT [...]
Genfit: GENFIT annonce le succès de son introduction en bourse sur le Nasdaq dans le cadre d’une offre globale d’American Depositary Shares aux États-Unis et d’un placement privé d’actions
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
27/03/2019
Mayzent ® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients with relapsing remitting MS [...]
MyoKardia Announces Pricing of Public Offering of Common Stock
26/03/2019
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious [...]
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
26/03/2019
CHARLESTON, S.C., March 26, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. All [...]
Harvard Bioscience To Showcase Products at Experimental Biology 2019
26/03/2019
All Three Commercial Units to Be Represented HOLLISTON, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to [...]
Lutronic Vision Engages World Renowned Retina Expert for R:GEN™ Pilot AMD Clinical Study
26/03/2019
-Key opinion leader Professor Robyn Guymer expected to serve as study’s principal investigator- BILLERICA, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Lutronic Vision (“Lutronic” or “the Company”), a wholly-owned [...]
Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
26/03/2019
MINNEAPOLIS, March 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common [...]
ImmuCell Corporation Announces Commencement of Public Offering of Common Stock
26/03/2019
PORTLAND, Maine, March 26, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]

Pages